EQUIOXX IMPORTANT SAFETY INFORMATION: As a class, nonsteroidal anti-inflammatory drugs may be associated with gastrointestinal, hepatic and renal toxicity. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. EQUIOXX has not been tested in horses less than 1 year of age or in breeding horses, or pregnant or lactating mares.
LEGEND IMPORTANT SAFETY INFORMATION: The safety of LEGEND has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. The following adverse reactions have been reported following intravenous injection: occasional depression, lethargy, and fever. Following intra-articular injection: lameness, joint effusion, joint or injection site swelling, and joint pain.
SURPASS IMPORTANT SAFETY INFORMATION: SURPASS topical cream is only approved for use in horses and has not been evaluated in breeding, pregnant, or lactating horses, or in horses under 1 year of age. Do not exceed the recommended dose.
HYALOVET AND HYVISC IMPORTANT SAFETY INFORMATION: A mild inflammatory response may occur post injection. For intra-articular injection in horses only. Do not use in horses intended for food.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
1. Oke S, McIlwraith CW. Review of the economic impact of osteoarthritis and oral joint-health supplements in horses, in Proceedings. AAEP 2010;56.
2. EQUIOXX product labels and FOI summaries and supplements
EQUIOXX®, SURPASS®, and LEGEND® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. HYALOVET® is a registered trademark of TRB Chemedica International S.A., Geneva Switzerland, used under license. HYVISC® is a registered trademark of Anika Therapeutics, Inc, used under license. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0114-2021-V3